ROVI — Laboratorios Farmaceuticos Rovi SA Balance Sheet
0.000.00%
- €2.62bn
- €2.71bn
- €763.75m
- 94
- 20
- 13
- 33
Annual balance sheet for Laboratorios Farmaceuticos Rovi SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 53.2 | 99 | 125 | 25.3 | 27.4 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 84.2 | 160 | 184 | 143 | 130 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Current Assets | 365 | 506 | 623 | 509 | 490 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 155 | 182 | 216 | 254 | 287 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 574 | 733 | 879 | 800 | 832 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 123 | 190 | 294 | 200 | 157 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 201 | 262 | 359 | 260 | 260 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Total Equity | 374 | 471 | 520 | 539 | 572 |
Total Liabilities & Shareholders' Equity | 574 | 733 | 879 | 800 | 832 |
Total Common Shares Outstanding |